Drug profile · INN
dolasetron mesylate
ANZEMET
dolasetron mesylate (ANZEMET) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — dolasetron mesylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dolasetron mesylate (ANZEMET) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Primary target: 5-hydroxytryptamine receptor 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dolasetron mesylate?
dolasetron mesylate (ANZEMET) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dolasetron mesylate?
ANZEMET is a marketed brand name for dolasetron mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dolasetron mesylate?
dolasetron mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.